Physician profile
Khalid Maqsood
NPI 1629047378
$7,616.06
in general payments reported to CMS, 2019-2025
32 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $733 · 2021: $926 · 2022: $834 · 2023: $1,140 · 2024: $1,678 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136 · Education: $43.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,135.76 |
| Education | $43.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,909.73 | 2019-2025 | |
| Pfizer INC. | $1,142.57 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $414.31 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $327.73 | 2019-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $325.02 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $307.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.70 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $289.48 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $198.18 | 2021-2024 | Zeposia |
| Vivus LLC | $179.30 | 2019-2024 | Pancreaze |
| Genzyme Corporation | $176.34 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $150.36 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $145.31 | 2021-2023 | |
| Ardelyx, INC. | $100.76 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $89.53 | 2019-2024 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $68.24 | 2021-2023 | Rebyota |
| Lilly USA, LLC | $56.06 | 2025 | Omvoh |
| Ucb, INC. | $53.76 | 2019-2020 | |
| Evoke Pharma, INC. | $47.75 | 2020-2022 | |
| Redhill Biopharma INC. | $45.67 | 2021-2022 | |
| Organon LLC | $42.46 | 2023-2024 | Hadlima |
| Phadia US INC. | $31.29 | 2023 | Immunocap |
| Intercept Pharmaceuticals, INC. | $28.86 | 2019 | |
| Novo Nordisk INC | $27.31 | 2025 | Wegovy |
| Exact Sciences Corporation | $27.18 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $26.85 | 2019 | |
| Ironwood Pharmaceuticals, INC | $24.23 | 2024 | |
| Shionogi INC | $22.98 | 2019 | |
| Madrigal Pharmaceuticals | $16.83 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $16.56 | 2019 | |
| Celltrion USA INC. | $15.05 | 2024 | Zymfentra |
| Regeneron Pharmaceuticals, INC. | $14.82 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Maqsood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.